There was one striking difference between 2020, year one of the COVID-19 pandemic, and 2021, year two: in the second year, vaccines became readily available.
Galecto terminates development for its lead candidate – Pharmaceutical Technology
Galecto CEO stated, “Given the impact of the results from the GALACTIC-1 trial on our future plans, we are currently evaluating resource allocation with the